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Abstract 
This is the first report from Pakistan of a case of bacteremia in a human due to P. fulva, an opportunistic infection with increased risk of a drug 
resistant phenotype. P. fulva was isolated from blood of a 45 years male admitted in surgical ICU. Isolate was identified by the MALDI-TOF-
MS and was extensively drug resistant (XDR) strain. Isolate was found negative for metallo β lactamase (MBL) and extended spectrum β 
lactamase (ESBL) types by phenotypic and polymerase chain reaction (PCR) assays. It was concluded that P. fulva is an emerging opportunistic 
pathogen. 
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Introduction 
Pseudomonas fulva is an opportunistic pathogen of 
the Pseudomonad group that rarely causes infection in 
man. It has mostly been reported from aquatic 
environments including rice seed, petroleum fields, oil 
brine and gills of the molluscs [1]. To date, four cases 
of infections with P. fulva have been reported in 
humans together with an outbreak of 19 patients in 
China over 3 years in which the of source the 
bacteremia was identified as contaminated (insulin, 
isosorbide dinitrate, and potassium magnesium 
aspartate with 5% glucose) solutions [2]. The case 
reports regarded isolation of bacterium from sputum of 
a patient with cystic fibrosis [3], from cerebral drainage 
of a case of meningitis [1], from the blood of a case of 
bacteremia [4] and from exudate from a soft tissue 
wound [5]. Infections with P. fulva are characterized by 
poor clinical outcomes: out of five cases including this 
case, only 2 patients survived. 
 
Case Report 
A 45 years male was admitted to the surgical 
Intensive Care Unit (ICU) of a tertiary care hospital, in 
Karachi, Pakistan following a road accident. The case 
was referred from a public hospital with post-surgical 
complications, history of head injury and fractured ribs 
and laceration wounds at various sites of the body 
together with fever and the need for mechanical 
ventilation. Total leucocyte count (TLC) was 16.5×109 
cells/L and septicemia was suspected. Blood was 
collected for microbiological culture (on the 18th day 
after surgery) and empirical treatment with 
Piperacillin/tazobactam and Vancomycin was initiated. 
The patient’s condition did not improve. Blood culture 
was processed manually and was positive for Gram-
negative bacilli on direct Gram-staining from the 
incubated blood culture bottle after 24 h of incubation 
showing slight turbidity. Sub-culturing on MacConkey 
and Blood agar plates revealed the growth of non-
hemolytic colonies on blood agar, with lactose negative 
colonies on MacConkey agar. Using a routine manual 
method and API 20NF kit (Biomerieux, Marcy I’Etoile 
France) the growth was identified as Pseudomonas 
putida. Before the complete identification, the patient 
died. However, the identification characteristics in this 
case, i.e. motile cells, oxidase positive (weak ±) 
colonies and water-soluble yellow pigments were not 
observed. Variable results for oxidase have previously 
been reported from negative, weak positive-to-positive 
for P. putida [4]. To confirm the identity, the isolate was 
submitted in duplicate to MALDI-TOF-MS (Microflex, 
Bruker Daltonics, Bremen, Germany) at the UCL 
Centre for Clinical Microbiology and identified as P. 
fulva. Antimicrobial susceptibility to the most common 
antipseudomonal drugs was determined by the disc 
diffusion method following the Clinical and Laboratory 
Standards Institute (CLSI) recommendations. The 
breaking points for Minimum Inhibitory 
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Concentrations (MICs) were used as described by 
Almuzara et al. and CLSI, [1,6]. The P. fulva isolate 
was resistant to piperacillin, piperacillin/tazobactam, 
ceftazidime, aztreonam, cefepime, carbapenems 
(meropenem and imipenem) amikacin, gentamicin, 
tobramycin and ciprofloxacin with the zones of 
inhibition of 7 mm, and was found sensitive to the 
Colistin by MIC method. The results of disc diffusion 
were confirmed by determination of MICs using Etest 
strip (BioMérieux, Lyon, France and M.I.C. Evaluator, 
Oxoid, Basingstoke, UK). The data (Table 1) revealed 
the strain of P. fulva as extensively drug resistant 
(XDR). Modified Hodge test (MHT) and Rapidec 
Carba NP (Biomerieux, Marcy-l‘Etoile, France) were 
used to identify carbapenemases and results were found 
negative. Isolate was subjected to 
Ethylenediaminetetraacetic acid (EDTA) double disc 
synergy test with Impipenem and Meropenem and 
Rosco kit test for Klebsiella pneumoniae 
carbapenemase (KPC) / metallo β lactamase (MBL) for 
P. aeruginosa and Acinetobacter species (ROSCO’s 
Diagnostic, Tassstrup, Denmark). It appeared positive 
for MBL using these phenotypic methods, however, 
production of MBLs could not be confirmed by the 
genotypic assay using primers VIM-like F-
GGTGTTTGGTCGCATATCGC, R-
CCATTCAGCCAGATCGGCATC, IMP-like F-
GGAATAGAGTGGCTTAATTC R-
CAACCAGTTTTGCCTTACC, and NDM-like F-
CACCTCATGTTTGAATTCGCC R-
CTCTGTCACATCGAAATCGC. Polymerase chain 
reaction (PCR) conditions were maintained as 
previously described [7-9]. The isolate was also found 
negative for extended spectrum β lactamase (ESBLs), 
PER and VEB types) by PCR method [10,11]. This 
suggests that the resistance mechanism was other than 
these β-lactamases. 
 
Discussion 
The members of Pseudomonas putida group are 
ubiquitously present in variety of environmental niches 
[12]. They are rarely involved in infections in human 
but few reports of bacteremia and infections of soft 
tissues have been emerged [13]. Studies state higher 
rate (46%) of VIM positive strains of this group from 
human specimens [1]. Furthermore, these species have 
been described as reservoirs for the dissemination of the 
antibiotic resistance genes to the more pathogenic 
species such as P. aeruginosa [13-15]. P. fulva is the 
less characterized member of this group which has 
scarcely been demonstrated as human pathogen. It is 
mainly due to its misidentification as Pseudomonas 
putida (99%) by the Vitek 2 system [1,2] resulting in its 
under reporting. In all the cases, P. fulva was identified 
either by 16S rRNA typing or MALDI-TOF-MS.  
The MALDI-TOF-MS has been validated by 
different researchers as an alternate assay for the 
accurate and reliable tool to distinguish P. fulva, from 
P. putida group (P. putida, P. fulva, P. monteilii, and P. 
mosselii) in comparison to sequencing16s rRNA, gyrB, 
or rpoD genes. It identifies P. fulva with 100% 
sensitivity and specificity among P. putida group [16-
18]. Hence, cautionary measures should be taken to 
identify an isolate when unusual biochemical results of 
Pseudomonas spp. are observed. Correct identification 
of the isolatesfrom samples may increase the number of 
cases caused by this species.  
History of the patient revealed that source of P. 
fulva may be traced back to hospital environment or 
contaminated intravenous solutions as described earlier 
[2]. Susceptibility pattern of our strain was slightly 
different to the previously isolated stains [1,2,19]. 
Almuzara et al. [1] reported susceptibility of P. fulva to 
Cefepime, Amikacin, Ciprofloxacin, and Colistin. 
However, in this case, the isolate was susceptible to 
Colistin only. The presence of MBL was also detected 
Table 1. Antibiotic susceptibility pattern (MIC) of P. fulva. 
Antibiotic MICs (µL/mL) Interpretation 
Piperacillin 128 Resistant 
Piperacillin-tazobactam 128/4 Resistant 
Ceftazidime > 32 Resistant 
Cefepime > 32 Resistant 
Aztreonam > 32 Resistant 
Imipenem > 32 Resistant 
Meropenem > 32 Resistant 
Tobramycin 32 Resistant 
Gentamicin 32 Resistant 
Amikacin 128 Resistant 
Ciprofloxacin 8 Resistant 
Colistin 0.5 Resistant 
 
Uddin et al. – Bacteremia caused by P. fulva       J Infect Dev Ctries 2018; 12(7):597-599. 
599 
by Rebolledo et al. [19] using phenotypic tests, EDTA 
double disc synergy test and ROSCO test, however, 
genotypic results did not affirm this finding in our case. 
Contrarily, the presence of blaVIM, MBL type was 
reported in previously isolated P. fulva strains [1,19].  
 
Conclusion 
The increasing isolation of P. fulva foreshadows the 
increased risk of this organism causing severe 
infections in critically ill patients. Due to capability of 
acquiring resistance determinants such as 
carbapenemase (VIM), it appears as an emerging threat 
to public health care facilitates. 
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